Impact of the revised International Prognostic Scoring System on the outcome of patients with acute myeloid leukemia with or without antecedent myelodysplastic syndrome

Leukemia

Volumn 28, Issue 3, 2014, Pages 723-725

  Stolzel F ^a   Kramer, M ^a   Mohr, B ^a   Wermke, M ^a   Bornhauser M ^a   Ehninger, G ^a   Schaich, M ^b   Platzbecker, U ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b Rems Murr Klinik   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LETTER; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM;

LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; TREATMENT OUTCOME;

EID: 84895816744     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.356     Document Type: Letter

References (12)

1. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
2. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.
3. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH et al. Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116: 354-365.
4. Schanz J, Tuchler H, Sole F, Mallo M, Luno E, Cervera J et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012; 30: 820-829.
5. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120: 2454-2465.
6. Deeg HJ, Scott BL, Fang M, Shulman HM, Gyurkocza B, Myerson D et al. Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. Blood 2012; 120: 1398-1408.
7. Lamarque M, Raynaud S, Itzykson R, Thepot S, Quesnel B, Dreyfus F et al. The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: The GFM experience. Blood 2012; 120: 5084-5085.
8. Rollig C, Thiede C, Gramatzki M, Aulitzky W, Bodenstein H, Bornhauser M et al. A novel prognostic model in elderly patients with acute myeloid leukemia: Results of 909 patients entered into the prospective AML96 trial. Blood 2010; 116: 971-978.
9. Schaich M, Parmentier S, Kramer M, Illmer T, Stolzel F, Rollig C et al. High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: Results of the prospective randomized AML2003 trial. J Clin Oncol 2013; 31: 2094-2102.
10. Stolzel F, Pfirrmann M, Aulitzky WE, Kaufmann M, Bodenstein H, Bornhauser M et al. Risk stratification using a new prognostic score for patients with secondary acute myeloid leukemia: Results of the prospective AML96 trial. Leukemia 2011; 25: 420-428.
11. Shaffer LG, McGowan-Jordan J, Schmid M. An International System for Human Cytogenetic Nomenclature (ISCN), 2013.
12. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21: 4642-4649..